Ariadne Wealth Management LP Invests $499,000 in Repligen Co. (NASDAQ:RGEN)

Ariadne Wealth Management LP purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) in the second quarter, HoldingsChannel reports. The institutional investor purchased 3,962 shares of the biotechnology company’s stock, valued at approximately $499,000.

A number of other large investors also recently modified their holdings of the business. Corient Private Wealth LLC raised its stake in shares of Repligen by 28.0% in the fourth quarter. Corient Private Wealth LLC now owns 7,011 shares of the biotechnology company’s stock valued at $1,261,000 after purchasing an additional 1,532 shares in the last quarter. Hsbc Holdings PLC grew its position in Repligen by 13.7% in the fourth quarter. Hsbc Holdings PLC now owns 8,102 shares of the biotechnology company’s stock valued at $1,458,000 after acquiring an additional 979 shares during the period. TD Asset Management Inc grew its position in Repligen by 4.1% in the fourth quarter. TD Asset Management Inc now owns 61,632 shares of the biotechnology company’s stock valued at $11,081,000 after acquiring an additional 2,413 shares during the period. Allianz Asset Management GmbH grew its position in Repligen by 25.6% in the fourth quarter. Allianz Asset Management GmbH now owns 9,712 shares of the biotechnology company’s stock valued at $1,746,000 after acquiring an additional 1,978 shares during the period. Finally, APG Asset Management US Inc. bought a new stake in Repligen in the fourth quarter valued at $1,827,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Up 2.0 %

NASDAQ:RGEN opened at $148.82 on Tuesday. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $8.32 billion, a price-to-earnings ratio of 595.28, a price-to-earnings-growth ratio of 4.23 and a beta of 0.94. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The stock’s 50 day moving average price is $148.80 and its two-hundred day moving average price is $153.15.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.53 EPS. Equities research analysts expect that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research report on Thursday, September 26th. Stephens restated an “overweight” rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Deutsche Bank Aktiengesellschaft upgraded Repligen from a “hold” rating to a “buy” rating and decreased their price target for the company from $180.00 to $155.00 in a report on Wednesday, June 26th. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Finally, UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.